Afatinib

FDA approves GILOTRIF™ (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations
Sacramento Bee, CA
Sat, 07/13/13 - 12:37 pm
non-small cell lung cancer
Gilotrif
Afatinib
Boehringer Ingelheim
FDA fast tracks two new lung cancer drugs
PM Live
Fri, 01/18/13 - 10:17 am
fast track
FDA
Boehringer Ingelheim
Astellas
Roche
Afatinib
Tarceva
non-small cell lung cancer
BI's cancer drug afatinib gets US fast-track review
Pharma Times, UK
Wed, 01/16/13 - 08:38 am
Afatinib
Boehringer Ingelheim
fast track
non-small cell lung cancer
Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib in Advanced Breast Cancer
PR-USA
Sat, 12/11/10 - 12:57 pm
Afatinib
breast cancer
Boehringer Ingelheim